GlassScriptPhysician profile
Myron G Davidson
NPI 1821078841
$20,123.46
in general payments reported to CMS, 2019-2025
42 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $2,628 · 2021: $3,675 · 2022: $2,679 · 2023: $2,670 · 2024: $2,730 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,264.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,154.30 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $5,082.23 | 2019-2025 | Biktarvy, Sunlenca, Yeztugo |
| Janssen Biotech, INC. | $2,945.03 | 2019-2023 | Symtuza, Prezcobix |
| Emd Serono, INC. | $883.62 | 2019-2025 | Serostim |
| Antares Pharma, INC. | $829.60 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $763.90 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Products, LP | $462.94 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $385.03 | 2019-2022 | |
| Theratechnologies INC. | $373.81 | 2022-2025 | Trogarzo, Egrifta |
| Astrazeneca Pharmaceuticals LP | $325.34 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $322.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $292.13 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $223.75 | 2022-2025 | Rexulti |
| Pfizer INC. | $212.23 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $180.89 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.89 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $175.96 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $158.56 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $139.39 | 2022-2024 | Quviviq |
| Endo Pharmaceuticals INC. | $133.24 | 2021 | |
| Eisai INC. | $120.67 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $92.61 | 2019-2020 | |
| Napo Pharmaceuticals INC | $87.58 | 2022-2025 | Mytesi |
| Exact Sciences Corporation | $85.60 | 2023-2025 | Cologuard Collection Kit |
| Tolmar, INC. | $79.00 | 2023-2025 | Jatenzo |
| Halozyme INC | $58.18 | 2023 | |
| Verity Pharmaceuticals INC. | $46.96 | 2024-2025 | Tlando |
| Bausch Health US, LLC | $33.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Lundbeck LLC | $27.88 | 2025 | Rexulti |
| Astellas Pharma US INC | $26.59 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $24.96 | 2025 | Nuzyra |
| Axsome Therapeutics, INC. | $21.71 | 2024 | Auvelity |
| Mylan Institutional INC. | $21.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.55 | 2019 | |
| Clarus Therapeutics INC. | $20.50 | 2021 | |
| Ibsa Pharma INC. | $18.25 | 2020 | |
| Glaxosmithkline, LLC. | $17.93 | 2024 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $17.71 | 2025 | Voquezna |
| Alkermes, INC. | $17.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.76 | 2025 | Keveyis |
| Abbvie INC. | $15.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myron Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.